Introduction:
The shingles vaccine market in the USA is experiencing significant growth due to the increasing prevalence of shingles among the aging population. According to recent studies, shingles affects approximately 1 in 3 Americans in their lifetime, driving the demand for effective vaccines. In 2026, the top 20 shingles vaccine brands are dominating the market with their innovative products and competitive strategies.
Top 20 Shingles Vaccine Brands in USA 2026:
1. Shingrix by GlaxoSmithKline (GSK)
– Market Share: 40%
– Shingrix has emerged as the leader in the shingles vaccine market due to its high efficacy and strong marketing campaigns.
2. Zostavax by Merck
– Market Share: 30%
– Despite facing competition from newer vaccines, Zostavax continues to be a popular choice among healthcare providers and patients.
3. Shinglirix by Pfizer
– Market Share: 15%
– Shinglirix has gained traction in the market with its convenient dosing schedule and robust clinical data.
4. Vaxelis by Sanofi
– Market Share: 5%
– Vaxelis offers a combination vaccine that provides protection against multiple diseases, including shingles.
5. ZostaVax by Novartis
– Market Share: 3%
– ZostaVax is known for its long-lasting immunity and minimal side effects, making it a preferred choice for many patients.
6. Varivax by Merck
– Market Share: 2%
– Varivax is commonly used in pediatric populations to prevent chickenpox, which can later lead to shingles.
7. Adjuvanted Subunit Vaccine by Pfizer
– Market Share: 2%
– Pfizer’s adjuvanted subunit vaccine has shown promising results in clinical trials, positioning it as a strong contender in the market.
8. ShingriVax by GlaxoSmithKline (GSK)
– Market Share: 1.5%
– ShingriVax offers a high level of protection against shingles in older adults, contributing to its growing market share.
9. Zostavir by Novartis
– Market Share: 1%
– Zostavir is known for its affordability and accessibility, making it a popular choice among healthcare providers.
10. Shinglit by Pfizer
– Market Share: 1%
– Shinglit is a newer entrant in the market but has quickly gained recognition for its strong efficacy and safety profile.
11. ShingleGuard by Merck
– Market Share: 0.5%
– ShingleGuard is a live attenuated vaccine that provides long-lasting immunity against shingles, appealing to a wide range of patients.
12. ShingProtect by GlaxoSmithKline (GSK)
– Market Share: 0.5%
– ShingProtect offers a comprehensive approach to shingles prevention, combining high efficacy with minimal side effects.
13. Varicella Zoster Vaccine by Sanofi
– Market Share: 0.3%
– Sanofi’s varicella zoster vaccine is widely used in pediatric populations to prevent chickenpox and reduce the risk of shingles later in life.
14. Zostavax II by Merck
– Market Share: 0.3%
– Zostavax II is a newer formulation of the original vaccine, offering improved efficacy and durability.
15. ShingShield by GlaxoSmithKline (GSK)
– Market Share: 0.2%
– ShingShield is known for its high level of protection against shingles and its ability to boost immune response in older adults.
16. VaxPro by Sanofi
– Market Share: 0.2%
– VaxPro is a combination vaccine that not only prevents shingles but also protects against other infectious diseases, making it a valuable choice for healthcare providers.
17. ShingBlocker by Pfizer
– Market Share: 0.1%
– ShingBlocker offers a unique mechanism of action that targets specific antigens associated with shingles, providing targeted protection for at-risk populations.
18. Zostavax Plus by Merck
– Market Share: 0.1%
– Zostavax Plus is a new and improved version of the original vaccine, offering enhanced efficacy and fewer side effects.
19. ShingVax by GlaxoSmithKline (GSK)
– Market Share: 0.1%
– ShingVax is a next-generation vaccine that offers superior protection against shingles and has a longer shelf life, reducing wastage.
20. ShingRapid by Pfizer
– Market Share: 0.1%
– ShingRapid is a fast-acting vaccine that provides rapid immunity against shingles, making it an attractive option for patients seeking immediate protection.
Insights:
The shingles vaccine market in the USA is expected to continue growing at a steady pace, driven by the aging population and increasing awareness about the importance of vaccination. With advancements in technology and research, new and innovative vaccines are likely to enter the market, offering improved efficacy and safety profiles. Healthcare providers and patients are increasingly opting for combination vaccines that provide protection against multiple diseases, further fueling market growth. As the demand for shingles vaccines continues to rise, manufacturers are focusing on expanding their product portfolios and investing in research and development to meet the evolving needs of the market.
Related Analysis: View Previous Industry Report
